@article{JTD585,
author = {Jair Bar and Iris Shiran and Damien Urban and Abed Agbarya and Amir Onn},
title = {Anti-angiogenic treatments in advanced NSCLC: back to the drawing board},
journal = {Journal of Thoracic Disease},
volume = {4},
number = {6},
year = {2012},
keywords = {},
abstract = {Sorafenib is a multi-kinase inhibitor, targeting the serine-theronine kinases c- and b-raf, and the tyrosine kinases VEGFR1-3, PDGF-beta, c-kit, RET and fms-like tyrosine kinase receptor 3 (Flt3). Thus, it inhibits multiple signaling pathways that are involved in tumor growth and spread, including tumor cell proliferation and survival, and angiogenesis. Sorafenib has proven efficacy as a single drug treatment for hepatocellular carcinoma (1) and renal cell carcinoma (2). It is being tested as a treatment for several other tumors, either as a single agent or as an addition to other therapeutic reagents. Several studies have reported its use in NSCLC patients.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/585}
}